CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
HIF-2alpha Inhibitor PT2385 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03216499
NCT03216499Phase 2Completed
CompareCT.gov

Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jul 13, 2017·Updated May 9, 2022

In Brief

A Phase 2 clinical trial evaluating HIF-2alpha Inhibitor PT2385, Pharmacological Study, and 2 other interventions for Recurrent Glioblastoma. Completed, enrolled 24 participants across 10 sites.

Detailed Summary

This phase II trial studies how well HIF-2 alpha inhibitor PT2385 works in treating patients with recurrent glioblastoma. HIF-2 alpha inhibitor PT2385 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Glioblastoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 13, 2017
Enrollment StartSep 14, 2017
Primary CompletionAug 31, 2019
Study CompletionJun 5, 2020
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.0 years ago

Interventions

HIF-2alpha Inhibitor PT2385drug

Given PO

Pharmacological Studyother

Correlative studies

Laboratory Biomarker Analysisother

Correlative studies

Pharmacogenomic Studyother

Correlative studies